Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;33(8):1590-1601.
doi: 10.1681/ASN.2022010080. Epub 2022 Jun 2.

Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease

Hae-Ryong Yun  1 , Young Su Joo  1 , Hyung Woo Kim  2 , Jung Tak Park  2 , Tae Ik Chang  3 , Nak-Hoon Son  4 , Tae-Hyun Yoo  2 , Shin-Wook Kang  2   5 , Suah Sung  6 , Kyu-Beck Lee  7 , Joongyub Lee  8 , Kook-Hwan Oh  9 , Seung Hyeok Han  2 ; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) investigators; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)
Collaborators, Affiliations

Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease

Hae-Ryong Yun et al. J Am Soc Nephrol. 2022 Aug.

Abstract

Background: An elevated coronary artery calcification score (CACS) is associated with increased cardiovascular disease risk in patients with CKD. However, the relationship between CACS and CKD progression has not been elucidated.

Methods: We studied 1936 participants with CKD (stages G1-G5 without kidney replacement therapy) enrolled in the KoreaN Cohort Study for Outcome in Patients With CKD. The main predictor was Agatston CACS categories at baseline (0 AU, 1-100 AU, and >100 AU). The primary outcome was CKD progression, defined as a ≥50% decline in eGFR or the onset of kidney failure with replacement therapy.

Results: During 8130 person-years of follow-up, the primary outcome occurred in 584 (30.2%) patients. In the adjusted cause-specific hazard model, CACS of 1-100 AU (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.04 to 1.61) and CACS >100 AU (HR, 1.42; 95% CI, 1.10 to 1.82) were associated with a significantly higher risk of the primary outcome. The HR associated with per 1-SD log of CACS was 1.13 (95% CI, 1.03 to 1.24). When nonfatal cardiovascular events were treated as a time-varying covariate, CACS of 1-100 AU (HR, 1.31; 95% CI, 1.07 to 1.60) and CACS >100 AU (HR, 1.46; 95% CI, 1.16 to 1.85) were also associated with a higher risk of CKD progression. The association was stronger in older patients, in those with type 2 diabetes, and in those not using antiplatelet drugs. Furthermore, patients with higher CACS had a significantly larger eGFR decline rate.

Conclusion: Our findings suggest that a high CACS is associated with significantly increased risk of adverse kidney outcomes and CKD progression.

Keywords: chronic renal disease; clinical nephrology; coronary artery disease; coronary calcification; vascular calcification.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Flow diagram of the study subjects.
Figure 2.
Figure 2.
The probability of kidney survival rates according to coronary artery calcification score categories. The probability of kidney survival rates was estimated with cumulative incidence function and compared by Gray’s test (P<0.001). CACS, coronary artery calcification score.
Figure 3.
Figure 3.
Cubic spline analysis for risk of adverse clinical events by coronary artery calcification score. Coronary artery calcification score was calculated as log transformation and expressed as coronary artery calcification score per 1-SD log.
Figure 4.
Figure 4.
Multivariable-adjusted hazard ratios for CKD progression according to coronary artery calcification score categories and per 1-SD log of coronary artery calcification score, stratified by subgroups. Each hazard ratio was adjusted for covariates including sex, age, Charlson comorbidity index, smoking status, education level, body mass index, etiology of kidney disease, BP, eGFR, total cholesterol, HDL cholesterol, LDL cholesterol, high-sensitivity C-reactive protein, medications (antihypertensive drugs and lipid-lowering drugs), phosphate, intact parathyroid hormone, urinary protein-to-creatinine ratio, and fibroblast growth factor-23. CAC, coronary artery calcification; CI, confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004 - PubMed
    1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. ; Chronic Kidney Disease Prognosis Consortium : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375: 2073–2081, 2010 - PMC - PubMed
    1. Grams ME, Astor BC, Bash LD, Matsushita K, Wang Y, Coresh J: Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J Am Soc Nephrol 21: 1757–1764, 2010 - PMC - PubMed
    1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. : Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034–2047, 2006 - PubMed
    1. Jankowski J, Floege J, Fliser D, Böhm M, Marx N: Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation 143: 1157–1172, 2021 - PMC - PubMed

Publication types

MeSH terms